We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00584909
Recruitment Status : Terminated (low accrual)
First Posted : January 2, 2008
Results First Posted : March 29, 2012
Last Update Posted : January 27, 2017
Information provided by (Responsible Party):
J. Michael Straughn, MD, University of Alabama at Birmingham

Brief Summary:
The main purpose of this study us to determine the best treatment for patients with endometrial cancer who are at an elevated risk for recurrence.

Condition or disease Intervention/treatment Phase
Uterine Cancer Drug: Paclitaxel and carboplatin combination Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Paclitaxel and Carboplatin in Patients With Intermediate-Risk Adenocarcinoma of the Endometrium
Study Start Date : March 2006
Primary Completion Date : September 2010
Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Uterine Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Open Label Drug: Paclitaxel and carboplatin combination
Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).

Primary Outcome Measures :
  1. Disease-free Survival [ Time Frame: 4 years - Median follow up time of 45.3 months ]
    Number of months of survival with no evidence of disease

Secondary Outcome Measures :
  1. Toxicity [ Time Frame: 4 years ]
    Toxicity secondary to paclitaxel and carboplatin based upon the NCI common toxicity criteria version

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have a elevated risk, surgical stage II, stage IC, grade 2 or 3 adenocarcinoma of the endometrium.
  • Patients must have undergone, a total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, and a pelvic and para-aortic lymphadenectomy.
  • Patients must have adequate organ function defined as:

    1. Platelets >/= 100,000/µ
    2. Granulocytes (ANC)>/= 1,500/µl
    3. Creatinine</= 1.6 mg/dl
    4. SGOT (AST) </= 3x upper limits of normal
    5. Bilirubin within institutional normal limits
  • Patients must have adequate performance status (ECOG performance status 0-2 or Karnofsky Performance Status >40)
  • Patients must be age 19 or greater and have signed informed consent.

Exclusion Criteria:

  • Patients with history of other malignancies within 5 years (except non- melanoma skin cancer or carcinoma-in-situ of the cervix) are ineligible.
  • Patients with high-risk histologic subtypes of endometrial cancer such as papillary serous or clear cell histology are ineligible.
  • Patients with histologic evidence of uterine sarcoma, including leiomyosarcoma, carcinosarcoma, endometrial stromal sarcoma, and adenosarcoma are ineligible.
  • Patients who have received past pelvic radiotherapy are ineligible.
  • Patients receiving any other investigational agents are ineligible.
  • Patients with known hypersensitivity to paclitaxel and/or carboplatin are ineligible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00584909

United States, Alabama
UAB Women's and Infant Center, 1700 6th Avenue South
Birmingham, Alabama, United States, 35233
Sponsors and Collaborators
University of Alabama at Birmingham
Principal Investigator: John M. Straughn, MD Assistant Professor, Dept of OB/Gyn, Division of GYN Oncology

Responsible Party: J. Michael Straughn, MD, Associate Professor, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00584909     History of Changes
Other Study ID Numbers: F060328016 (UAB 0604)
UAB 0604 ( Other Identifier: UAB Department study number )
First Posted: January 2, 2008    Key Record Dates
Results First Posted: March 29, 2012
Last Update Posted: January 27, 2017
Last Verified: January 2017

Additional relevant MeSH terms:
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action